Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  2. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  3. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  4. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  5. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  6. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  7. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  8. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  9. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  10. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  11. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  12. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  13. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  14. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  15. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  16. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  17. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  18. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  19. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  20. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  21. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  22. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  23. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  24. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  25. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  26. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  27. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  28. Li ZX, et al. 2022. Arch Virol. :. PubMed
  29. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  30. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  31. Wang D, et al. 2018. Immunity. 48:659. PubMed
  32. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  33. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  34. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  35. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  36. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  37. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  38. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  39. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  40. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  41. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  42. Dong L, et al. 2021. Cancer Cell. . PubMed
  43. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  44. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  45. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  46. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  47. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  48. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  49. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  50. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  51. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  52. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  53. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  54. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  55. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  56. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  57. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  58. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  59. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  60. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  61. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  62. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  63. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  64. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  65. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  66. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  67. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  68. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  69. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  70. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  71. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  72. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  73. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  74. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  75. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  76. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  77. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  78. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  79. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  80. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  81. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  82. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  83. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  84. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  85. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  86. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  87. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  88. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  89. Solanki A, et al. 2018. Development. 145. PubMed
  90. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  91. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  92. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  93. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  94. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  95. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  96. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  97. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  98. He X, et al. 2021. Small. 17:e2007165. PubMed
  99. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  100. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  101. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  102. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  103. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  104. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  105. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  106. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  107. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  108. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  109. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  110. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  111. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  112. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  113. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  114. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  115. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  116. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  117. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  118. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  119. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  120. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  121. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  122. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  123. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  124. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  125. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  126. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  127. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  128. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  129. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  130. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  131. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  132. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  133. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  134. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  135. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  136. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  137. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  138. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  139. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  140. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  141. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  142. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  143. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  144. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  145. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  146. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  147. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  148. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  149. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  150. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  151. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  152. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  153. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  154. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  155. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  156. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  157. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  158. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  159. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  160. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  161. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  162. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  163. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  164. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  165. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  166. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  167. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  168. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  169. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  170. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  171. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  172. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  173. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  174. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  175. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  176. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  177. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  178. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  179. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  180. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  181. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  182. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  183. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  184. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  185. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  186. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  187. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  188. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  189. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  190. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  191. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  192. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  193. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  194. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  195. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  196. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  197. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  198. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  199. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  200. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  201. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  202. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  203. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  204. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  205. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  206. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  207. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  208. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  209. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  210. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  211. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  212. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  213. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  214. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  215. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  216. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  217. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  218. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  219. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  220. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  221. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  222. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  223. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  224. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  225. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  226. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  227. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  228. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  229. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  230. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  231. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  232. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  233. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  234. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  235. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  236. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  237. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  238. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  239. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  240. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  241. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  242. Chen B, et al. 2021. Cell. 184:6262. PubMed
  243. Smith LK, et al. 2021. Elife. 10:. PubMed
  244. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  245. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  246. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  247. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  248. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  249. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  250. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  251. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  252. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  253. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  254. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  255. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  256. Zheng Y, et al. 2022. Transl Res. :. PubMed
  257. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  258. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  259. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  260. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  261. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  262. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  263. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  264. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  265. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  266. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  267. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  268. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account